ESPR - Esperion Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$3.19
DETAILS
HIGH:
$3.28
LOW:
$3.16
MEDIAN:
$3.16
CONSENSUS:
$3.19
UPSIDE:
1.92%
About Esperion Therapeutics, Inc. (https://www.esperion.com)
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Sheldon L. Koenig | President, Chief Executive Officer & Director | 1966 | $1,427,583 USD |
| Benjamin Halladay | Chief Financial Officer | 1986 | $755,083 USD |
| Benjamin O. Looker | Chief Legal and Corporate Affairs Officer | 1982 | $696,350 USD |
| John Harlow | Chief Commercial Officer | 1976 | $582,940 USD |
| Betty Jean Swartz | Chief Business Officer | – | – |
| Glenn Brame | Chief Technical Operations Officer | 1957 | – |
| LeAnne Bloedon | Vice President & Head of Development | – | – |
| Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development | – | – |
| Tiffany Aldrich | Associate Director of Corporate Communications | – | – |